Skip to main content
    S

    Solventum Corp. (SOLV)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE

    $88.65
    -0.43 (-0.48%)

    Market Cap: $15.14B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Solventum Corp. (SOLV) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Solventum reported revenue of $8.32B for the fiscal year ended Dec 31, 2025, up 0.9% from the year before. That year, net income was $1.56B with a net margin of 18.7%, operating cash flow was $369.00M and free cash flow was -$10.00M. The quarter ended Sep 30, 2026 had revenue of $1.95B and net income of -$12.00M.

    Revenue and Margins

    The operating margin was 26.2% in the fiscal year ended Dec 2025, the highest of the 6 years shown. Over the 5 years to Dec 2025, revenue grew from $7.28B, a compound annual rate of 2.7%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$8.32B+0.9%53.5%26.2%18.7%
    Dec 2024$8.25B+0.7%55.6%12.6%5.8%
    Dec 2023$8.20B+0.8%57.3%20.6%16.4%
    Dec 2022$8.13B-0.5%57.7%20.8%16.5%
    Dec 2021$8.17B+12.2%60.2%23.0%17.9%
    Dec 2020$7.28BN/A59.3%19.6%15.6%
    Annual, fiscal years ended Dec 2020 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 225.7% from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Revenue$8.32B$8.25B$8.20B$8.13B$8.17B$7.28B
    Cost of revenue$3.87B$3.66B$3.50B$3.44B$3.25B$2.97B
    Gross profit$4.45B$4.59B$4.69B$4.70B$4.92B$4.32B
    Research and development$739.00M$775.00M$758.00M$767.00M$766.00M$719.00M
    Operating income$2.18B$1.04B$1.69B$1.69B$1.88B$1.43B
    Net income$1.56B$479.00M$1.35B$1.34B$1.46B$1.14B
    EBITDA$2.63B$1.53B$2.23B$2.27B$2.48B$2.03B
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$1.95B$2.21B$2.01B$2.00B$2.10B$2.16B$2.07B$2.08B$2.08B$2.08B$2.02B$2.04B
    Gross profit$1.06B$1.29B$1.10B$1.03B$1.14B$1.18B$1.11B$1.12B$1.17B$1.14B$1.17B$1.16B
    Operating income$68.00M$181.00M$81.00M$125.00M$1.69B$214.00M$152.00M$136.00M$275.00M$244.00M$381.00M$406.00M
    Net income-$12.00M$92.00M$13.00M$63.00M$1.27B$90.00M$137.00M$31.00M$122.00M$89.00M$237.00M$272.00M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $5.04B exceeded cash and equivalents by $4.16B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Total assets$14.29B$14.46B$13.94B$13.59B$14.07BN/A
    Current assets$3.86B$3.25B$2.52B$2.23B$2.19BN/A
    Cash and equivalents$878.00M$762.00M$194.00M$61.00M$91.00MN/A
    Total liabilities$9.24B$11.50B$2.28B$1.85B$2.02BN/A
    Short-term debt$0$200.00M$0$27.00M$29.00MN/A
    Long-term debt$5.04B$7.81B$0N/AN/AN/A
    Shareholder equity$5.05B$2.96B$11.67B$11.74B$12.06BN/A
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$14.16B$14.24B$14.10B$14.29B$13.97B$15.07B$14.53B$14.46B$14.74B$14.58B$14.71B$13.94B
    Total liabilities$9.36B$9.44B$9.13B$9.24B$8.99B$11.43B$11.27B$11.50B$11.55B$11.71B$10.86B$2.28B
    Cash and equivalents$451.00M$403.00M$561.00M$878.00M$1.64B$492.00M$534.00M$762.00M$772.00M$897.00M$996.00M$194.00M
    Shareholder equity$4.80B$4.80B$4.97B$5.05B$4.99B$3.65B$3.26B$2.96B$3.19B$2.87B$3.85B$11.67B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, capital expenditures exceeded operating cash flow, leaving negative free cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Operating cash flow$369.00M$1.19B$1.92B$1.68B$2.20B$2.03B
    Capital expenditures$379.00M$380.00M$290.00M$251.00M$277.00M$271.00M
    Free cash flow-$10.00M$805.00M$1.63B$1.43B$1.93B$1.75B
    Investing cash flow$2.80B-$380.00M-$230.00M-$253.00M-$278.00M$228.00M
    Financing cash flow-$3.06B-$240.00M-$1.55B-$1.46B-$1.96B-$2.21B
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$177.00M$227.00M-$189.00M$95.00M$76.00M$169.00M$29.00M$219.00M$169.00M$355.00M$442.00M$547.00M
    Capital expenditures$80.00M$83.00M$84.00M$63.00M$97.00M$110.00M$109.00M$127.00M$93.00M$58.00M$102.00M$88.00M
    Free cash flow$97.00M$144.00M-$273.00M$32.00M-$21.00M$59.00M-$80.00M$92.00M$76.00M$297.00M$340.00M$459.00M
    Last 12 quarters

    Frequently Asked Questions About SOLV

    What is Solventum's annual revenue?

    Solventum reported revenue of $8.32B for the fiscal year ended Dec 31, 2025.

    How fast is Solventum's revenue growing?

    Revenue was up 0.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 0.8%.

    Is Solventum profitable?

    Yes. Solventum reported net income of $1.56B for the fiscal year ended Dec 31, 2025, with a net margin of 18.7%.

    How much free cash flow does SOLV generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $369.00M minus capital expenditures of $379.00M produced free cash flow of -$10.00M.

    How much debt does Solventum have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $5.04B, short-term debt of $0 and cash and equivalents of $878.00M.